Eloquent medication trial#
Eloquent medication license#

Infusion reactions occurred in 3 patients (5%) in the elotuzumab group. A total of 65% of the patients in each group had infections. 27% in the control group), anemia (10% vs. The most common grade 3 or 4 adverse events were neutropenia (13% in the elotuzumab group vs.

The overall response rate was 53% in the elotuzumab group as compared with 26% in the control group (odds ratio, 3.25 95% CI, 1.49 to 7.11). The hazard ratio for disease progression or death in the elotuzumab group as compared with the control group was 0.54 (95% confidence interval, 0.34 to 0.86 P=0.008). After a minimum follow-up period of 9.1 months, the median progression-free survival was 10.3 months in the elotuzumab group and 4.7 months in the control group. ResultsĪ total of 117 patients were randomly assigned to the elotuzumab group (60 patients) or the control group (57 patients). The primary end point was investigator-assessed progression-free survival. Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor. The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The most trusted, influential source of new medical knowledge and clinical best practices in the world.

Eloquent medication license#

Information and tools for librarians about site license offerings. Valuable tools for building a rewarding career in health care. The authorized source of trusted medical research and education for the Chinese-language medical community. The most advanced way to teach, practice, and assess clinical reasoning skills. Information, resources, and support needed to approach rotations - and life as a resident. The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams.

NEW! Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Ĭoncise summaries and expert physician commentary that busy clinicians need to enhance patient care.

Eloquent medication trial#

NEW! A digital journal for innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.